Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Robert E. Swillo"'
Autor:
George P. Vlasuk, James K. Hennan, Gwen A. Morgan, Stephen J. Gardell, Eric I. Rossman, Joel Kantrowitz, Jørgen Petersen, Robert E. Swillo, John A. Butera
Publikováno v:
Journal of Cardiovascular Pharmacology and Therapeutics. 14:207-214
The antiarrhythmic dipeptide, GAP-134, ([2S,4R]-1[2-aminoacetyl]-4-benzamido-pyrrolidine-2-carboxylic acid) was evaluated in canine ischemia/reperfusion model. In dogs subjected to 60-minute ischemia and 4-hour reperfusion, GAP-134 was administered 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49b76e6227e5d070ebcdd5e4ca525079
https://doi.org/10.1177/1074248409340779
https://doi.org/10.1177/1074248409340779
Autor:
Gwen A. Morgan, Kun Liu, James K. Hennan, Eric I. Rossman, Hal S. Feldman, John A. Butera, Julie A. Krueger, Ketil Haugan, Matthew Gruver, Robert E. Swillo, Joel Kantrowitz, Stephen J. Gardell, Jørgen Petersen
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 329:1127-1133
Gap junction uncoupling can alter conduction pathways and promote cardiac re-entry mechanisms that potentiate many supraventricular arrhythmias, such as atrial fibrillation (AF) and atrial flutter (AFL). Our objective was to determine whether GAP-134
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a37f8a52c4329340fe2fa3469579cdda
https://doi.org/10.1124/jpet.108.150102
https://doi.org/10.1124/jpet.108.150102
Autor:
Thomas M. Antrilli, Gwen A. Morgan, Robert E. Swillo, Girija Krishnamurthy, James K. Hennan, David L. Crandall, Hassan Mahmoud Elokdah, Jean S Bauer
Publikováno v:
Biochemical and Biophysical Research Communications. 311:904-908
Plasminogen activator inhibitor-1 (PAI-1) is the major physiological inhibitor of tissue plasminogen activator (tPA) and is elevated in diseases of vascular remodeling. In this study, we describe an inhibitor of active PAI-1, WAY-140312. Using fluore
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a006371b9a510cd5e44b1131e51743ca
https://doi.org/10.1016/j.bbrc.2003.10.088
https://doi.org/10.1016/j.bbrc.2003.10.088
Autor:
Li Di, Bjarne Due Larsen, Eric I. Rossman, Eugene Lvovich Piatnitski Chekler, Robert E. Swillo, James K. Hennan, Christine Huselton, John A. Butera, Gwen A. Morgan
Publikováno v:
Bioorganicmedicinal chemistry letters. 19(16)
In an effort to discover potent, orally bioavailable compounds for the treatment of atrial fibrillation (AF) and ventricular tachycardia (VT), we developed a class of gap-junction modifiers typified by GAP-134 (1, R(1)=OH, R(2)=NH(2)), a compound cur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5a01d2742b89a42160fd15f2342e37f
https://pubmed.ncbi.nlm.nih.gov/19616941
https://pubmed.ncbi.nlm.nih.gov/19616941
Autor:
Edward H. Kerns, Eric I. Rossman, Leonard McDonald, James K. Hennan, Qiang Wang, Bjarne Due Larsen, Christine Huselton, Li Di, John A. Butera, Kun Liu, Jørgen Søøøøøberg Petersen, Asaf Alimardanov, Gwen A. Morgan, Rayomand Unwalla, Robert E. Swillo
Publikováno v:
Journal of medicinal chemistry. 52(4)
Rotigaptide (3) is an antiarrhythmic peptide that improves cardiac conduction by modifying gap-junction communication. Small molecule gap-junction modifiers with improved physical properties were identified from a Zealand Pharma peptide library using
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::566ea6a7cc1a58626de0e37de647e136
https://pubmed.ncbi.nlm.nih.gov/19175320
https://pubmed.ncbi.nlm.nih.gov/19175320
Autor:
Eric I Rossman, Kun Liu, Gwen A Morgan, Robert E Swillo, John Butera, Matthew Gruver, Joel Kantrowitz, Ketil Haugan, Jorgen S Petersen, James K Hennan
Publikováno v:
Circulation. 116
Atrial fibrillation (AF) and atrial flutter (AFL), the most common sustained cardiac arrhythmias, are major contributors to cardiovascular morbidity and mortality in the adult population. Current pharmacologic treatment of AF/AFL is only moderately s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8b8ae47430a03dd9d30a6cac2ff90746
https://doi.org/10.1161/circ.116.suppl_16.ii_392-c
https://doi.org/10.1161/circ.116.suppl_16.ii_392-c
Autor:
Courtney E. Leik, George P. Vlasuk, Robert E. Swillo, Gwen A. Morgan, Robert G. Schaub, David L. Crandall, Gray D. Shaw, James K. Hennan, Jonathan M. Brooks
Publikováno v:
Thrombosis and haemostasis. 95(3)
SummaryUnder high shear arterial blood flow von Willebrand Factor (vWF) binds the platelet receptor glycoprotein (GP) Ibα, leading to platelet adhesion, activation and thrombosis. Blockade of vWF-GPIbα interactions by GPG-290 was investigated in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad96d8ad61c62888000dfe43ff9174c4
https://pubmed.ncbi.nlm.nih.gov/16525575
https://pubmed.ncbi.nlm.nih.gov/16525575
Autor:
Joel Kantrowitz, John A. Butera, James C. Keith, Gwen A. Morgan, Hal S. Feldman, Phil J. Wang, David L. Crandall, Robert E. Swillo, Ketil Haugan, James K. Hennan, Aqel Abu-Qare, Robert P. Smith, Robert G. Schaub, Bjarne Due Larsen
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 317(1)
The antiarrhythmic and cardioprotective effect of increasing gap junction intercellular communication during ischemia/reperfusion injury has not been studied. The antiarrhythmic peptide rotigaptide (previously ZP123), which maintains gap junction int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92ca0d459ad0d69e7fb149a3f74823a4
https://pubmed.ncbi.nlm.nih.gov/16344331
https://pubmed.ncbi.nlm.nih.gov/16344331
Autor:
Mauricio Leal, Robert E. Swillo, Gregory S. Friedrichs, Amy L. Hreha, David L. Crandall, Thomas M. Antrilli, Gwen A. Morgan, James K. Hennan, Allena J. Ji, Hassan Mahmoud Elokdah
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 314(2)
We tested a novel, orally active inhibitor of plasminogen activator inhibitor-1 (PAI-1) in a canine model of electrolytic injury. Dogs received by oral gavage either vehicle (control) or the PAI-1 inhibitor PAI-039 [{1-benzyl-5-[4-(trifluoromethoxy)p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4647c1e13cd951223ae99022215f1f12
https://pubmed.ncbi.nlm.nih.gov/15860572
https://pubmed.ncbi.nlm.nih.gov/15860572
Autor:
John A. Butera, Bjarne Due Larsen, James K. Hennan, Edward Kerns, Li Di, Asaf Alimardanov, Robert E. Swillo, Gwen A. Morgan, Kun Liu, Qiang Wang, Eric I. Rossman, Rayomand Unwalla, Leonard McDonald, Christine Huselton, Jørgen S. Petersen
Publikováno v:
Journal of Medicinal Chemistry; Feb2009, Vol. 52 Issue 4, p908-911, 4p